Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma
To evaluate the safety and efficacy of irinotecan and capecitabine in Asian subjects with inoperable hepatocellular carcinoma.
Carcinoma, Hepatocellular
DRUG: Irinotecan plus capecitabine
Overall response rate, Week 6
Time to progression, Weeks 6, 12, 18, 24, 36, and 1 year|Duration of overall response, Weeks 6, 12, 18, 24, 36, and 1 year|Overall tumour growth control rate, Weeks 6, 12, 18, 24, 36, and 1 year|Overall survival, Weeks 6, 12, 18, 24, 36, and 1 year|Adverse events, Weeks 6, 12, 18, 24, 36, and 1 year|Physical exam, Weeks 6, 12, 18, 24, 36, and 1 year|Laboratory tests, Weeks 6, 12, 18, 24, 36, and 1 year
To evaluate the safety and efficacy of irinotecan and capecitabine in Asian subjects with inoperable hepatocellular carcinoma.